Jaques David A, Spahr Laurent, Berra Gregory, Poffet Vincent, Lescuyer Pierre, Gerstel Eric, Garin Nicolas, Martin Pierre-Yves, Ponte Belen
Internal Medicine Department, Geneva University Hospitals, Geneva, Switzerland.
Gastroenterology Division, Medicine Specialties Department, Geneva University Hospitals, Geneva, Switzerland.
Nephrology (Carlton). 2019 Feb;24(2):170-180. doi: 10.1111/nep.13226.
Acute kidney injury (AKI) is a frequent complication in cirrhotic patients. As serum creatinine is a poor marker of renal function in this population, we aimed to study the utility of several biomarkers in this context.
A prospective study was conducted in hospitalized patients with decompensated cirrhosis. Serum creatinine (SCr), Cystatin C (CystC), NGAL and urinary NGAL, KIM-1, protein, albumin and sodium were measured on three separate occasions. Renal resistive index (RRI) was obtained. We analyzed the value of these biomarkers to determine the presence of AKI, its aetiology [prerenal, acute tubular necrosis (ATN), or hepatorenal (HRS)], its severity and a composite clinical outcome at 30 days (death, dialysis and intensive care admission).
We included 105 patients, of which 55 had AKI. SCr, CystC, NGAL (plasma and urinary), urinary sodium and RRI at inclusion were independently associated with the presence of AKI. SCr, CystC and plasma NGAL were able to predict the subsequent development of AKI. Pre-renal state showed lower levels of SCr, NGAL (plasma and urinary) and RRI. ATN patients had high levels of NGAL (plasma and urinary) as well as urinary protein and sodium. HRS patients presented an intermediate pattern. All biomarkers paralleled the severity of AKI. SCr, CystC and plasma NGAL predicted the development of the composite clinical outcome with the same performance as the MELD score.
In patients with decompensated cirrhosis, early measurement of renal biomarkers provides valuable information on AKI aetiology. It could also improve AKI diagnosis and prognosis.
急性肾损伤(AKI)是肝硬化患者常见的并发症。由于血清肌酐在该人群中并非肾功能的良好标志物,我们旨在研究几种生物标志物在此情况下的效用。
对失代偿期肝硬化住院患者进行了一项前瞻性研究。在三个不同时间点测量血清肌酐(SCr)、胱抑素C(CystC)、中性粒细胞明胶酶相关脂质运载蛋白(NGAL)及尿NGAL、肾损伤分子-1(KIM-1)、蛋白质、白蛋白和钠。获取肾阻力指数(RRI)。我们分析这些生物标志物的值,以确定AKI的存在、其病因[肾前性、急性肾小管坏死(ATN)或肝肾综合征(HRS)]、其严重程度以及30天的综合临床结局(死亡、透析和重症监护病房入住)。
我们纳入了105例患者,其中55例有AKI。纳入时的SCr、CystC、NGAL(血浆和尿液)、尿钠和RRI与AKI的存在独立相关。SCr、CystC和血浆NGAL能够预测AKI的后续发展。肾前状态显示SCr、NGAL(血浆和尿液)和RRI水平较低。ATN患者的NGAL(血浆和尿液)以及尿蛋白和钠水平较高。HRS患者呈现中间模式。所有生物标志物均与AKI的严重程度平行。SCr、CystC和血浆NGAL预测综合临床结局的发展,其表现与终末期肝病模型(MELD)评分相同。
在失代偿期肝硬化患者中,早期检测肾脏生物标志物可提供有关AKI病因的有价值信息。它还可以改善AKI的诊断和预后。